Home » Topics » Science » Drug design, drug delivery and technologies

Drug design, drug delivery and technologies
RSS

RPR Gencell and IntraImmune Therapies enter drug development agreement

June 21, 1996

Megabios issued worldwide license to lipid-DNA complexes

June 21, 1996

Drug development agreement reached by Megabios and Pfizer

June 21, 1996

HemaSure/American Red Cross Biomedical Services alliance

June 14, 1996

Exelixis acquires rights to P Element technology

June 14, 1996

Bayer/CV Therapeutics antiinflammatory drug agreement

June 14, 1996

Bristol-Myers Squibb/Garvan Institute of Medical Research collaboration

June 14, 1996

Ingenex granted phase II SBIR grant

June 14, 1996

Neoprobe and Dow enter licensing agreement

June 7, 1996

Research agreement: TCPI and the University of Kansas

June 7, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 20, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
LIT-002 is strong candidate for autism and neuropathic pain
BioWorld Science
Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...